Historical Review: Cannabis Medicine Has Thousands of Years of History But Modern Clinical Research Is Just Beginning

Despite thousands of years of medicinal cannabis use, modern clinical research remained in its infancy as of 2005, with most studies being small, poorly controlled, or using unsatisfactory cannabinoid formulations, though new possibilities were emerging from endocannabinoid system discoveries.

Robson, P·Handbook of experimental pharmacology·2005·Moderate EvidenceReview

Medical Cannabis (1546)Pain (645)Harm Reduction (776)

Quick Facts

Study Type

Review

Evidence

Moderate Evidence

Sample

Not reported

What This Study Found

This review traced the arc of medicinal cannabis from its prominence in 19th century Western medicine through its early 20th century prohibition and 1960s recreational explosion, to the current state of clinical research.

The author identified major methodological challenges that had kept clinical evidence weak: studies tended to be small, imperfectly controlled, and often used synthetic cannabinoid analogs or smoked herbal material with uncertain composition and irregular bioavailability.

New research opportunities were emerging from three developments: the discovery of the endocannabinoid system, expanding knowledge of cannabinoid pharmacology, and a more sympathetic political environment in several countries. Future therapeutic targets were expected to extend beyond symptom relief into disease modification, with cannabinoids showing particular promise for inflammatory and neurodegenerative conditions.

Key Numbers

Cannabis medicinal use documented across several thousand years and multiple cultures. Most clinical studies described as small and imperfectly controlled. Future targets identified: inflammatory and neurodegenerative conditions.

How They Did This

Comprehensive narrative review covering the historical development and current status of medicinal cannabis research. Examined legal controls, existing clinical trial evidence across multiple conditions, safety considerations, and future research directions.

Why This Research Matters

This review honestly assessed the gap between thousands of years of anecdotal evidence for medical cannabis and the thin base of rigorous clinical research. By identifying why research had lagged, including the "pariah drug" status and methodological challenges, it helped set the agenda for more rigorous future studies.

The Bigger Picture

The observation that medical cannabis research was still "in its infancy" in 2005 explains why many questions about cannabis therapeutics remain only partially answered today. The methodological challenges identified, particularly around standardization and delivery methods, continue to affect cannabis research.

What This Study Doesn't Tell Us

As a broad historical and contemporary review, it could not deeply evaluate evidence for any specific condition. The assessment of research quality was qualitative rather than systematic. The review reflected the state of evidence as of 2005.

Questions This Raises

?Can cannabis-based medicines be standardized well enough for conventional pharmaceutical development?
?Will cannabinoids prove effective for disease modification in inflammatory and neurodegenerative conditions?

Trust & Context

Key Stat:: Scientific evaluation of medicinal cannabis in humans described as "still in its infancy" in 2005
Evidence Grade:: Comprehensive historical and clinical review. Provides excellent context but is broad rather than deeply analytical for any specific condition.
Study Age:: Published in 2005. Clinical cannabis research has expanded considerably since then, though many of the methodological challenges identified here persist.
Original Title:: Human studies of cannabinoids and medicinal cannabis.
Published In:: Handbook of experimental pharmacology, 719-56 (2005)
Authors:: Robson, P(2)
Database ID:: RTHC-00204

Evidence Hierarchy

Meta-Analysis / Systematic Review

Randomized Controlled Trial

Cohort / Case-Control

Cross-Sectional / ObservationalSnapshot without intervening

This study

Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Why isn't there more clinical research on medical cannabis?

This review identified several barriers: cannabis's "pariah drug" legal status made research difficult, most studies were small and poorly controlled, and standardized pharmaceutical-grade cannabis preparations were not widely available. The political and research landscape has improved since 2005 but challenges remain.

What conditions show the most promise for cannabis treatment?

As of this 2005 review, the strongest evidence existed for symptom relief (pain, nausea, spasticity). The author identified inflammatory and neurodegenerative conditions as the most promising future targets for disease-modifying applications of cannabinoids.

Cite This Study

RTHC-00204·https://rethinkthc.com/research/RTHC-00204

APA

Robson, P. (2005). Human studies of cannabinoids and medicinal cannabis.. Handbook of experimental pharmacology, 719-56.

MLA

Robson, P. "Human studies of cannabinoids and medicinal cannabis.." Handbook of experimental pharmacology, 2005.

RethinkTHC

RethinkTHC Research Database. "Human studies of cannabinoids and medicinal cannabis." RTHC-00204. Retrieved from https://rethinkthc.com/research/robson-2005-human-studies-of-cannabinoids

Access the Original Study

View on PubMed

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.

← Back to Research Database